The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...

But for a long time China’s people struggled to get hold of Wegovy because the country’s regulators had not approved it. Some ...

Health Canada has approved Novo Nordisk’s semaglutide injection, Wegovy, to reduce the risk of non-fatal myocardial ...

Few companies garner as much reliable attention as Novo Nordisk ( NVO) does these days. With a bull market coinciding with a ...

Novo Nordisk A/S is cutting back on recruiting in Denmark after reaching the limits of its home country’s labor market in the ...

Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or ...

The Biden administration on Tuesday proposed that weight-loss drugs be paid for by Medicaid and Medicare, potentially making ...

The first prescription for the drug in China will reportedly be issued at a public hospital in Shanghai this week and will ...

According to Reuters and CNN, Novo Nordisk announced Monday that it has launched its popular obesity drug Wegovy in China, ...

Novo Nordisk faces challenges in weight-loss sector, but acquisition and strong diabetes portfolio position it for future ...

Novo Nordisk's Wegovy launch in China begins in Shanghai at $194 per four-injection pack, significantly cheaper than U.S.

Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.